Immunomedics Shares Up 96% Following News Co. Stopped ASCENT Trial Early Due To Overwhelming Efficacy; Jefferies Sees Event As De-Risking Given SG Is Now Well Positioned To Get Accelerated Approval
Benzinga Newsdesk